For individuals and families affected by mitochondrial disease, accessing appropriate care, medications, and equipment can be complex. Because mito is rare and often multi-systemic, patients may face insurance delays or denials for tests, treatments, or therapies that are medically necessary but not well understood by payers.

As healthcare costs continue to rise, both public and private insurers require stronger clinical justification for services and medications. Common cost-control strategies include:

• • Prior authorization
  • Utilization review
  • Drug formularies
  • Denials of coverage for off-label or rare-use medications
  • Step therapy (fail-first requirements)
  • Tiered drug benefits

Denials are most often seen for:

• • Medications – especially compounded formulations, high-cost mitochondrial supplements, or medications prescribed off-label
  • Diagnostics – such as genetic or metabolic testing not routinely covered
  • Services and therapies – including rehabilitation or nutrition support beyond plan limits
  • Durable medical equipment (DME) – like mobility aids, feeding tubes, or respiratory support deemed “not medically necessary”

Understanding the language and structure of your health plan can help you – and your healthcare team – respond effectively when coverage issues arise.

Prior Authorization

A requirement from your insurance company that your doctor must get approval before providing a test, medication, or treatment. This step is meant to confirm the care is medically necessary, but it can delay access – especially for complex or rare conditions like mito.

Utilization Review

An evaluation by your insurer to decide whether a healthcare service is necessary, appropriate, and efficient.

Reviews can happen:

• • Before care (prospective) – e.g., pre-approval for a genetic test
  • During care (concurrent) – e.g., while inpatient or receiving IV therapy
  • After care (retrospective) – e.g., reviewing a past claim for coverage

Drug Formulary

A list of medications your plan covers.

• • Drugs not listed may require an appeal or prior authorization.
  • Some mitochondrial supplements, compounded medications, or brand-name drugs may not appear on the formulary.

Off-Label Prescription

When a medication is prescribed for a use, dose, or age group not specifically listed on its FDA label. This is common in rare diseases like mito, where there may not be an approved drug for a symptom (for example, modafinil for fatigue or coenzyme Q10 formulations). Off-label use is legal and often medically appropriate–but insurers may deny coverage unless well-supported by documentation.

Step Therapy

Also called “fail-first”, this policy requires patients to try a lower-cost drug before the insurer will approve a more expensive one. In our community, this could mean being asked to try a standard medication (most likely not designed for mitochondrial disease) that may be less effective or not tolerated before accessing a drug that better fits the patient’s metabolic needs.

Tiered Drug Benefits

Insurers group medications into cost “tiers.”

• • Tier 1: Generic, lowest cost
  • Tier 2: Preferred brand-name
  • Tier 3–5: Non-preferred or specialty medications, highest copay or coinsurance Because mito medications and supplements may be specialty or compounded, they often fall into higher tiers.

An appeal should be filed by the patient, caregiver, or healthcare provider when coverage is denied and one or more of the following conditions apply:

1. Medical Necessity

Is the treatment, service, or medication medically necessary for your mito symptoms or disease management? Your provider’s letter should explain how the intervention improves function, prevents regression, or maintains quality of life.

2. Coverage Eligibility

Is the item or service typically covered under the plan? If your plan documents are unclear or do not specifically mention the therapy or drug, it’s worth filing an appeal.

3. Clerical Errors or Missing Information

Denials can result from missing documentation or coding errors.

• • Always request the denial letter in writing
  • Review for incorrect patient details, diagnosis codes, or service dates
  • Ask your provider’s office to resubmit with corrections or added notes

4. Cost or Affordability Concerns

Has your copay or coinsurance become unaffordable, especially for high-cost mitochondrial therapies? Many drug manufacturers and foundations offer copay, discount, or free-drug assistance programs for patients with rare or chronic conditions. You can find this information for each approved mitochondrial disease therapy on umdf.org’s “Medications” tab.

These strategies–drawn from clinicians and patient advocates working with mitochondrial disease–can help improve your chances of approval or appeal success:

• • Work with subspecialists familiar with mito.
    Neurologists, geneticists, or metabolic specialists can provide detailed clinical notes that strengthen appeals.
  • Document in detail.
    Include how the therapy or drug directly impacts mitochondrial function, fatigue, exercise tolerance, or organ stability.
  • Use specific language.
    When writing letters of medical necessity, reference the insurance policy and include key phrases like “medically necessary to maintain baseline function” or “prevents irreversible regression.”
  • Leverage Electronic Medical Records templates.
    Ask your healthcare provider to use letter templates that automatically pull in medical details for efficiency and consistency.
  • Know your resources.
    Check GoodRx, NeedyMeds, or manufacturer programs for denied medications or off-label therapies. While mitochondrial disease therapies may not be included, you may find other supportive treatments. You can find financial support information for all mitochondrial disease related therapies under the specific drug name on the “Medications” tab of www.umdf.org
  • Appeal persistently.
    Many initial denials are reversed upon appeal – especially when new documentation or peer-reviewed literature is submitted. If you receive a denial for a mitochondrial disease therapy when you believe you meet all the necessary requirements, please know you don’t have to face the appeals process alone. UMDF is here to support you with tools, resources, and guidance to help navigate insurance appeals. Our goal is to ensure that patients and families have the best chance of accessing the treatments they need. Reach out to UMDF Support for assistance at (888) 900-6486 or support@umdf.org.

· State Insurance Commissioners: https://content.naic.org/

· Department of Labor Health Benefits: https://www.askebsa.dol.gov/WebIntake/

· Patient Advocate Foundation (PAF): https://www.patientadvocate.org/

· National Organization for Rare Disorders (NORD): https://rarediseases.org/

· Global Genes: https://globalgenes.org/

· GoodRx: https://www.goodrx.com/

· NeedyMeds: https://www.needymeds.org/

For the mito community, persistence and documentation are key. Insurance denials are not the end of the road–they are often an invitation to educate the insurer about your condition and advocate for the medically necessary care you deserve.